Concepedia
Statistics
Publications
16
Citations
481
H-Index
12
Active since
2001
Affiliations
Johnson & Johnson (United States)(Current)
University of Saskatchewan
Saskatchewan Cancer Agency
Chengdu University of Information Technology
Chengdu University of Technology
Hui Huang is an author at Johnson & Johnson (United States) specializing in medicine, medicinal chemistry, and pharmacology.
Publications per year
2001–2024
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 89 citations
Medicine, Medicinal Chemistry, Pharmacology +13
Neutrophils and B Cells Express XCR1 Receptor and Chemotactically Respond to Lymphotactin
Hui Huang, Fang Li, Chantelle Cairns et al. · Biochemical and Biophysical Research Communications · 2001 · 67 citations
Life Sciences, Cell Biology, Immunology +11
Pyrido[2,3-<i>d</i>]pyrimidin-5-ones: A Novel Class of Antiinflammatory Macrophage Colony-Stimulating Factor-1 Receptor Inhibitors
Hui Huang, Daniel A. Hutta, James M. Rinker et al. · Journal of Medicinal Chemistry · 2009 · 41 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
Synergistic effect of adoptive T-cell therapy and intratumoral interferon γ-inducible protein-10 transgene expression in treatment of established tumors
Hui Huang, Yongqing Liu, Jim Xiang · Cellular Immunology · 2002 · 38 citations
Medicine, Immunology, Oncology +14
Synergistic effect of lymphotactin and interferon γ‐inducible protein‐10 transgene expression in T‐cell localization and adoptive T‐cell therapy of tumors
Hui Huang, Jim Xiang · International Journal of Cancer · 2004 · 38 citations
Medicine, Immunology, Oncology +17
1–5 of 16